• 1
    Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 71221 e4.
  • 2
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 3
    Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 9911000.
  • 4
    Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 13647.
  • 5
    El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 117185.
  • 6
    Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007; 102: 276776.
    Direct Link:
  • 7
    Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 173641.
  • 8
    Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 156980.
  • 9
    Ljótsson B, Hedman E, Andersson E et al. Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial. Am J Gastroenterol 2011; 106: 148191.
  • 10
    Craske MG, Wolitzky-Taylor KB, Labus J et al. A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther 2011; 49: 41321.
  • 11
    Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115: 126371.
  • 12
    Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984; 2: 12324.
  • 13
    Svedlund J, Sjodin I, Ottosson JO, Dotevall G. Controlled study of psychotherapy in irritable bowel syndrome. Lancet 1983; 2: 58992.
  • 14
    Blanchard EB, Greene B, Scharff L, Schwarz-McMorris SP. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul 1993; 18: 12532.
  • 15
    Shaw G, Srivastava ED, Sadlier M, Swann P, James JY, Rhodes J. Stress management for irritable bowel syndrome: a controlled trial. Digestion 1991; 50: 3642.
  • 16
    Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004; 72: 110013.
  • 17
    Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 36778.
  • 18
    Hungin AP. Self-help interventions in irritable bowel syndrome. Gut 2006; 55: 6034.
  • 19
    Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 177098.
  • 20
    Lindfors P, Unge P, Nyhlin H et al. Long-term effects of hypnotherapy in patients with refractory irritable bowel syndrome. Scand J Gastroenterol 2012; 47: 41420.
  • 21
    Lindfors P, Unge P, Arvidsson P et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012; 107: 27685.
  • 22
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): II437.
  • 23
    Gonsalkorale WM. Gut-directed hypnotherapy: the Manchester approach for treatment of irritable bowel syndrome. Int J Clin Exp Hypn 2006; 54: 2750.
  • 24
    Simrén M, Ringstrom G, Bjornsson ES, Abrahamsson H. Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. Psychosom Med 2004; 66: 2338.
  • 25
    Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 5539.
  • 26
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 27
    Toner BB, Stuckless N, Ali A, Downie F, Emmott S, Akman D. The development of a cognitive scale for functional bowel disorders. Psychosom Med 1998; 60: 4927.
  • 28
    Gonsalkorale WM, Toner BB, Whorwell PJ. Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome. J Psychosom Res 2004; 56: 2718.
  • 29
    Antonovsky A. The structure and properties of the sense of coherence scale. Soc Sci Med 1993; 36: 72533.
  • 30
    Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003; 52: 16239.
  • 31
    Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002; 97: 95461.
    Direct Link:
  • 32
    Palsson OS, Turner MJ, Johnson DA, Burnett CK, Whitehead WE. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002; 47: 260514.
  • 33
    Galovski TE, Blanchard EB. The treatment of irritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback 1998; 23: 21932.
  • 34
    Jackson JL, Chamberlin J, Kroenke K. Predictors of patient satisfaction. Soc Sci Med 2001; 52: 60920.
  • 35
    Dorn SD, Morris CB, Schneck SE et al. Development and validation of the irritable bowel syndrome satisfaction with care scale. Clin Gastroenterol Hepatol 2011; 9: 106571.
  • 36
    Jerndal P, Ringstrom G, Agerforz P et al. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil 2010; 22: 646-e179.
  • 37
    Revicki DA. Patient assessment of treatment satisfaction: methods and practical issues. Gut 2004; 53 (Suppl 4): iv404.
  • 38
    Fass R, Fullerton S, Naliboff B, Hirsh T, Mayer EA. Sexual dysfunction in patients with irritable bowel syndrome and non-ulcer dyspepsia. Digestion 1998; 59: 7985.
  • 39
    Ringström G, Agerforz P, Lindh A, Jerlstad P, Wallin J, Simrén M. What do patients with irritable bowel syndrome know about their disorder and how do they use their knowledge? Gastroenterol Nurs 2009; 32: 28492.
  • 40
    Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain 1983; 17: 3344.
  • 41
    Robinson ME, Riley JL 3rd, Myers CD et al. The Coping Strategies Questionnaire: a large sample, item level factor analysis. Clin J Pain 1997; 13: 439.
  • 42
    Olden K, DeGarmo RG, Jhingran P et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2002; 97: 313946.
    Direct Link:
  • 43
    Mercer M, Brinich MA, Geller G et al. How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 13844.